KROS (Keros Therapeutics) Other Current Liabilities: $3.46 Mil (As of Mar. 2026)


KROS Keros Therapeutics Inc KROS
30 GF Score
Price $11.65
! 3 Warning Signs
View Full Analysis

What is Keros Therapeutics Other Current Liabilities?

Keros Therapeutics KROS +5.72% 30 Other Current Liabilities is $3.46 Mil as of Mar. 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Keros Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $3.46 Mil.

Keros Therapeutics's quarterly other current liabilities declined from Sep. 2025 ($9.16 Mil) to Dec. 2025 ($6.09 Mil) and declined from Dec. 2025 ($6.09 Mil) to Mar. 2026 ($3.46 Mil).

Keros Therapeutics's annual other current liabilities increased from Dec. 2023 ($8.21 Mil) to Dec. 2024 ($10.55 Mil) but then declined from Dec. 2024 ($10.55 Mil) to Dec. 2025 ($6.09 Mil).

Keros Therapeutics Other Current Liabilities Related Terms

Keros Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Keros Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keros Therapeutics Other Current Liabilities Chart

Keros Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 2.58 5.56 8.21 10.55 6.09

Keros Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.82 8.51 9.16 6.09 3.46
KROS
30GF Score
Keros Therapeutics Inc KROS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keros Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $3.46 Mil mean?
Keros Therapeutics (KROS) has a Other Current Liabilities of $3.46 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Keros Therapeutics.
Is Keros Therapeutics' Other Current Liabilities too high?
Keros Therapeutics' current Other Current Liabilities is $3.46 Mil. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' Other Current Liabilities compare to CDXS and CAMP?
Keros Therapeutics' Other Current Liabilities of $3.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Keros Therapeutics. Keros Therapeutics's current Other Current Liabilities is $3.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current Other Current Liabilities of $3.46 Mil. The current Other Current Liabilities is $3.46 Mil. Keros Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Other Current Liabilities is $3.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Keros Therapeutics Business Description

Address 1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score

Get the complete analysis for KROS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.65
Price